Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer

Summary

In patients with acute cancer-associated thrombosis, current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Among 1,247 patients with acute venous thromboembolism (VTE) enrolled in the prospective Swiss Venous Thromboembolism Registry (SWIVTER) II from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, 83 (26%) prior cancer surgery, and 63 (20%) recurrent VTE. Long-term anticoagulation treatment for >12 months was more often planned in patients with versus without cancer (47% vs. 19%; p<0.001), with recurrent cancer-associated versus first cancer-associated VTE (70% vs. 41%; p<0.001), and with metastatic versus non-metastatic cancer (59% vs. 31%; p<0.001). In patients with cancer, recurrent VTE (OR 3.46; 95%CI 1.83–6.53), metastatic disease (OR 3.04; 95%CI 1.86–4.97), and the absence of an acute infection (OR 3.55; 95%CI 1.65–7.65) were independently associated with the intention to maintain anticoagulation for >12 months. In conclusion, long-term anticoagulation treatment for more than 12 months was planned in less than half of the cancer patients with acute VTE. The low rates of long-term anticoagulation in cancer patients with a first episode of VTE and in patients with non-metastatic cancer require particular attention.

Keywords

Anticoagulation - cancer - venous thromboembolism

• References

• 1 Khorana AA, Francis FW, Culakova E. et al. Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. Cancer 2007; 110: 2339-2346.
• 2 Ambrus JL, Ambrus CM, Mink IB. et al. Causes of death in cancer patients. J Med 1975; 6: 61-64.
• 3 Chew HK, Wun T, Harvey DJ. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
• 4 Sorensen HT, Mellemkjaer L, Olsen JH. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343: 1846-1850.
• 5 Levitan N, Dowlati A, Remick SC. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-291.
• 6 Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: A systematic review of randomized controlled trials. Thrombosis Res 2009; 123: 837-844.
• 7 van Dongen CJJ, van den Belt AGM, Prins MH. et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. The Cochrane Database of Systematic Reviews. 2004 4: CD001100.pub2.
• 8 Sandhu R, Pan CX, Wun T. et al. The Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Primary Bladder Cancer. Cancer 2010; 116: 2596-2603.
• 9 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 10 Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
• 11 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
• 12 Prandoni P, Lensing AWA, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
• 13 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th ed.). Chest 2008; 133: 454S-545S.
• 14 Lyman GH, Khorana AA, Falanga A. et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. J Clin Oncol 2007; 25: 5490-5505.
• 15 Spirk D, Banyai M, Jacomella V. et al. Outpatient management of acute deep vein thrombosis: Results from the OTIS-DVT registry. Thromb Res. 2011 prepublished online.
• 16 Joffe HV, Kucher N, Tapson VF. et al. Few predictors of massive deep vein thrombosis. Thromb Haemost 2005; 94: 986-990.
• 17 Imberti D, Agnelli G, Ageno W. et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 2008; 93: 273-278.
• 18 Spirk D, Husmann M, Willenberg T. et al. Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep-vein thrombosis: Results from the OTIS-DVT Registry. Thromb Haemost 2011; 105: 239-244.
• 19 Palareti G, Legnani C, Lee A. et al. A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. Thromb Haemost 2000; 84: 805-810.